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Abstract
Since the ﬁrst reports describing the injection of recombinant adeno-associated viral (AAV) vectors in the murine eye, the ad-
vancement of the ﬁeld has been enormous resulting in the correction of several animal models of retinal diseases. The recent de-
velopment of ‘‘pseudotyped’’ AAV vectors with transduction characteristics that best ﬁt the correction of speciﬁc retinal disease
phenotypes and of sophisticated systems for tight regulation of gene expression expands on the potentiality of this delivery system
for the eye.
 2003 Elsevier Science Ltd. All rights reserved.
1. Recombinant vectors based on AAV serotypes
Recombinant adeno-associated viral (AAV) vectors
are promising tools for gene transfer applications (Mo-
nahan & Samulski, 2000). They derive from a single-
stranded DNA virus which is a non-human pathogen
(Berns, 1996). Eight diﬀerent isolates have been de-
scribed to date. Four (AAV1-4) have been isolated as
contaminants of human adenoviral cultures and one
from a human condylomatous lesion (AAV5) (Bantel-
Schaal & zur Hausen, 1984). AAV6 appears as an ar-
tefact hybrid between AAV1 and 2 (Xiao et al., 1999).
Very recently, sequences from two novel serotypes
(AAV7 and 8) have been isolated from rhesus monkey
tissues and have been used to create recombinant vec-
tors (Gao et al., 2002).
The best characterized AAV vector, which is cur-
rently employed in a clinical trial for FIX deﬁciency,
derives from AAV2 (Atchinson, Casto, & Hammon,
1965). AAV2-mediated transduction appears safe and
stable in various tissues of animal models although
levels of gene transfer are often disappointing. One
AAV production strategy, based on transient transfec-
tion of the diﬀerent vector components in trans (Xiao,
Li, & Samulski, 1998), allows for the exchange of the
surface proteins (capsid) between diﬀerent serotypes.
This results in hybrid vectors with the same genome
encoding for the therapeutic gene (i.e. from AAV2)
packaged in capsids from diﬀerent AAV serotypes
(namely AAV2/1–8) (Fig. 1).
The use of vectors based on diﬀerent AAV serotypes
has mainly two advantages. Pre-existing immunity to
one serotype may be circumvented using a diﬀerent
capsid. In addition, AAV ‘‘pseudotype’’ transduction
characteristics, such as onset and intensity of gene ex-
pression as well as tissue tropism, depend on the capsid.
In mice in vivo, AAV2/1 and 2/7 vectors transduce
muscle very eﬃciently (Chao et al., 2000; Gao et al.,
2002; Rabinowitz et al., 2002), while AAV2/5 enters the
airway from the apical side (Zabner et al., 2000) and
AAV2/8 is the most eﬃcient AAV vector for liver-
directed gene transfer (Gao et al., 2002) (Fig. 1).
Therefore, the capsid inﬂuences the events leading to
transduction, including vector entry in the target cell
through binding to a speciﬁc receptor, intracellular
traﬃcking, nuclear entry and DNA double strand syn-
thesis (Rabinowitz & Samulski, 2000).
2. AAV vectors in the retina
The eye is an attractive target for gene therapies
(Bennett & Maguire, 2000), being small, enclosed and
immune privileged. In addition, a number of inherited
diseases aﬀecting the eye have known gene defects; there
*Tel.: +11-39-081-613-2229; fax: +11-39-081-613-2351.
E-mail address: auricchio@tigem.it (A. Auricchio).
0042-6989/03/$ - see front matter  2003 Elsevier Science Ltd. All rights reserved.
doi:10.1016/S0042-6989(02)00676-4
Vision Research 43 (2003) 913–918
www.elsevier.com/locate/visres
are well-characterized animal models for many of these
conditions; and many of the diseases progress slowly,
therefore allowing for timely delivery of a potential
treatment. Retinal diseases amenable to gene therapies
are generally characterized by neuronal degeneration
(i.e. retinitis pigmentosa) or by ocular neovasculariza-
tion (i.e. diabetic retinopathy and age-related macular
degeneration). Gene-based strategies to arrest or revert
retinal diseases are generally aiming at gene replace-
ment/targeting or at releasing a soluble factor exerting a
neurotrophic/anti-angiogenic eﬀect. In the ﬁrst case,
gene transfer has to occur in the speciﬁc cell type where
the defect is localized, in the latter any retinal or ocular
cell type in the proximity of the lesion can be transduced
and used as a factory for production of the secreted
therapeutic protein (Fig. 2).
AAV vectors, mainly based on serotype 2, have been
tested in the retina (Ali et al., 1996, 1998; Bennett,
Duan, Engelhardt, & Maguire, 1997; Bennett et al.,
1999; Dreyer, Vorwerk, Zurakowski, Simon, & Bennett,
1999; Flannery et al., 1997; Grant, Ponnazhagan, Wang,
Srivastava, & Li, 1997; Sarra et al., 2002). AAV2 vectors
transduce the retina of various animal models eﬃciently
and stably resulting in the successful correction of sev-
eral forms of retinitis pigmentosa (Acland et al., 2001;
Ali et al., 2000) and ocular neovascularization (Auric-
chio et al., in press; Bainbridge et al., 2002; Mori et al.,
2002; Raisler, Berns, Grant, Beliaev, & Hauswirth,
2002). It is worth mentioning that Sarra et al. (2001)
showed that gene transfer in the rds mouse had no sig-
niﬁcant eﬀect on photoreceptor cell loss despite the im-
provements in morphology and function (Ali et al.,
2000), suggesting that, at least in this case, successful
gene therapy may depend upon intervention in early
stages of disease and upon accurate control of transgene
expression. Subretinal injections of AAV2 vectors in
mice and non-human primates (NHP) result mainly in
targeting of the retinal pigment epithelium (RPE) and
photoreceptor layer (Ali et al., 1996; Bennett et al., 1999;
Flannery et al., 1997), while intravitreal administration
allows preferential transduction of Muller and retinal
ganglion cells (Ali et al., 1996, 1998; Auricchio et al.,
2001; Dreyer et al., 1999; Flannery et al., 1997).
The exchange of the capsid between diﬀerent AAV
serotypes results in modiﬁcations of their retinal trans-
duction characteristics (Auricchio et al., 2001; Rabino-
witz et al., 2002; Yang et al., 2002). Following AAV
subretinal administration in mice, the AAV1 capsid fa-
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Fig. 2. Scheme of a gene therapy strategy for eye diseases using soluble
molecules. A recombinant vector encoding a secreted protein is de-
livered to the eye. The retina (red, thick line) transduction results in the
secretion of the therapeutic protein in the adjacent spaces including
ocular ﬂuids. AC: anterior chamber ﬂuid; V: vitreous.
Fig. 1. Schematic representation of ‘‘pseudotyped’’ AAV production and targeting. Transfection in the packaging cells of the plasmids containing
the AAV genome (with the therapeutic gene contained between the viral inverted terminal repeats, ITRs), the packaging sequences (the cap genes
encoding for the capsids and the rep open reading frames belonging to serotype 2 to allow the most eﬃcient packaging of a viral genome with AAV2
ITRs), and the helper functions (not shown) results in production of recombinant virions. The hybrid virions containing the genome of one serotype
(i.e. AAV2) and a diﬀerent capsid (AAV2/1–8) have tropism dependent on the capsid sequence.
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vours RPE transduction, while AAV5 allows more eﬃ-
cient gene transfer in photoreceptors and RPE than
AAV2 (Fig. 3). In addition, the vectors capsid inﬂu-
ences the onset of gene expression: AAV2/1-mediated
expression starts more rapidly (24–48 h after vector
administration) than AAV2 (two to four weeks) and
AAV2/5 is intermediate (two weeks) between the two.
Taking into account the slow kinetic of AAV2 expres-
sion in the eye when compared to other AAV serotypes,
the latter may be preferable for the correction of retinal
diseases in animal models where an immediate onset of
gene expression is required. For instance, the rod pho-
toreceptor degeneration present in the rd mouse (bear-
ing a mutation in the phosphodiesterase b subunit)
(Chang et al., 2002) is complete by three weeks after
birth, requiring that gene replacement occurs in the
photoreceptors immediately after birth in order to pre-
serve the retinal architecture. The description of retinal
transduction by vectors based on various AAV sero-
types (Auricchio et al., 2001; Rabinowitz et al., 2002;
Yang et al., 2002) will certainly impact on the choice of
the appropriate AAV to use in animal models. For in-
stance, AAV pseudotypes may allow NHP cones
transduction, which are normally spared by AAV2 gene
transfer (Bennett et al., 1999). In conclusion, once con-
ﬁrmed in the NHP retina, the knowledge of AAV ser-
otypes transduction characteristics will prove crucial to
extend retinal gene transfer to humans.
3. AAV-mediated secretion of therapeutic proteins in the
eye
Intraocular injections of AAV2 encoding a neuro-
trophic (Green et al., 2001; Liang et al., 2001; Liang
et al., 2001; McGee Sanftner, Abel, Hauswirth, &
Flannery, 2001) or anti-angiogenic molecule (Auricchio
et al., in press; Bainbridge et al., 2002; Mori et al., 2002;
Raisler et al., 2002) results in detectable expression of
the molecule exerting the appropriate biological activity
in the eye. Interestingly, intravitreal or subretinal ad-
ministration of the vector does not signiﬁcantly impact
on the levels of soluble protein measured in the vitreous
space or anterior chamber (Fig. 4) (Auricchio et al.,
2002).
The retinal neovascularization of the mouse model of
retinopathy of prematurity (ROP) (Smith et al., 1994)
peaks between post-natal day 19 and 21 and then re-
gresses. Testing an anti-angiogenic gene-based therapy
in the ROP eye requires rapid onset of gene expression.
We successfully treated the retinas of ROP mice with
AAV2/1 vectors encoding three diﬀerent anti-angiogenic
molecules (Fig. 5) (Auricchio et al., in press), conﬁrming
that vectors with an AAV1 capsid trigger a rapid onset
of gene expression in the retina. Interestingly, similar
results have been obtained in the same model using an
AAV2 vector (with slow onset of gene expression in the
adult murine retina), suggesting that the newborn hyp-
oxic retina may oﬀer the cellular environment suitable
for rapid conversion of the AAV genome in a tran-
scriptionally active form (Raisler et al., 2002).
4. AAV-mediated pharmacological regulation of gene
expression in the eye
Whether gene therapy is used to exogenously replace
a mutated gene in the eye or to provide a soluble factor
Fig. 3. Fluorescence microscopy evaluation of EGFP expression four weeks post-subretinal injection with AAV2 (panel A), AAV5 (panel B), AAV2/
5 (panel C) and AAV2/1 (panel D) CMV-EGFP. AAV2, AAV5 and AAV2/5 target photoreceptors (in onl) and RPE (although only occasional RPE
cells are targeted by AAV2); AAV2/1 targets RPE. rpe: retinal pigment epithelium; onl: outer nuclear layer; inl: inner nuclear layer.
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Fig. 4. Constitutive secretion of Epo in the eye following subretinal or
intravitreal administration of AAV in nude rats. Epo levels (n ¼ 5/
group) in the anterior chamber ﬂuid (AC), vitreous ﬂuid (V) or from
lysed retinas ðRÞ were assessed four weeks after intravitreal or subre-
tinal administration of AAV. Mean values are depicted inside each
bar.
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with therapeutic activity, one major hurdle to overcome
is obtaining appropriate levels of gene expression. The
cargo capacity of most gene therapy vectors, including
AAV, limits the possibility to include large endogenous
gene regulatory elements. For this reason, a number of
gene expression systems that are inducible upon the
administration of a small molecule drug have been de-
vised (for a comprehensive review see (Clackson, 2000)).
These systems are generally based on two elements: an
engineered transcription factor whose activity is con-
trolled by a small molecule drug and a target gene whose
expression is driven by the regulated transcription fac-
tor. Pharmacological regulation of gene expression is
hampered by the risks of the drugs frequent adminis-
trations (for this reason, novel molecules with improved
eﬃcacy and reduced side eﬀects are being developed)
and by the possible ‘‘leakiness’’ (gene expression in the
absence of the inducer) of the system.
In one system, the small molecule drug is rapamycin,
which mediates the formation of heterodimers between
FKBP (FK506 binding protein) and FRAP (FKBP-
rapamycin associated protein). By fusing FKBP to a
DNA binding domain (ZFHD1) and FRAP to a tran-
scriptional activation domain (p65 from NF-jB), re-
constitution of a functional transcription factor and
expression of a target gene occur in the presence of ra-
pamycin (Pollock et al., 2000; Rivera et al., 1996). This
system is entirely made of human components theoret-
ically reducing the risk for immune responses in a gene
therapy setting. It has been recently tested in the rodent
and NHP retina (Auricchio et al., 2002). Two AAV
vectors, encoding the transcription factor (AAV2-CMV-
TF1nc) and the target gene (AAV2-Z12-rhEpo-2S6)
respectively were produced. The gene encoding Ery-
thropoietin (Epo), a soluble protein with functional ac-
tivity and measurable with a commercial Elisa, was
selected and a mixture of the two vectors was injected in
the subretinal space of rats and NHP. Epo expression
in the anterior chamber ﬂuid was absent in the absence
of the dimerizer rapamycin, and inducible in a dose
dependent way upon administration. In addition, upon
drug withdrawal, Epo levels in the ocular ﬂuids dropped
to levels similar to basal (Fig. 6). Finally, recombinant
Epo leaking from the ocular environment into the gen-
eral circulation is minimal. Similar results were obtained
by us and others (Dejneka et al., 2001; McGee Sanftner
et al., 2001) using the tetracycline inducible system de-
livered to the retina via viral vectors.
Pharmacologically regulated systems therefore pro-
vide useful means to gain control over time and level of
gene expression in the eye.
5. Conclusion
Proof of principal has recently been provided that
gene delivery using AAV2 can restore vision in a large
animal model of retinal disease. In addition, AAV vec-
tors have been successfully tested in the eye of a number
of rodent models and they are being evaluated in the
NHP retina. Issues related to the safety of the vector, the
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Fig. 5. Inhibition of neovascularization in ROP retinas treated with
AAV2/1 vectors. Eyes from ROP animals injected at post-natal (P) P2-
4 and sacriﬁced at P19 were enucleated, ﬁxed and paraﬃn embedded.
The number of vascular nuclei extending from the internal limiting
membrane into the vitreous was counted in serial sections on either
side of the optic nerve. The higher the number of nuclei the higher is
the neovascularization. Mean values are depicted inside each bar. The
vector transgene and number of eyes analyzed are listed under each bar
(endo: endostatin; PEDF: pigment epithelial derived factor; TIMP-3:
tissue inhibitor of metalloproteinase 3). P -values for all experimental
groups as compared to control were less than 0.0001 as calculated
using the Students t-test.
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Fig. 6. Secretion of Epo in the anterior chamber ﬂuid and serum of
one NHP after subretinal administration of AAV encoding Epo under
the control of the dimerizer-inducible system and following induction
with rapamycin. Both eyes have been injected subretinally with a 1:1
mixture of the dual vector system. The left (solid triangle) received one-
quarter of the dose given to the right (empty square). Secretion of Epo
in the anterior chamber ﬂuid of both eyes (upper panel) has been
followed over time following vector administration and rapamycin
injection at day 56.
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evaluation of new serotypes potentially more appropri-
ate to speciﬁc retinal applications and the regulation of
gene delivery have not been completely solved. Never-
theless, the possibility to test AAV mediated therapies in
humans aﬀected with severe forms of retinal diseases
seems close and appears now as a tangible option for the
treatment of diseases otherwise inevitably leading to
blindness.
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